Part: 12         Session: 145678910111213141516171819202122         Page 599600601602603604605606607608609610611612613614615616617618619620621622623624625626627628629630631632633634635636637638639640641642643644645646647648649650651652653654655656657658659660661662663 of 999

or have you other figures, or have you given up?”

Now, this is something you instigated?

Yes. That's right.

Dr. Gutterman has such standing in the medical profession that he will be listened to?

Well, he'd be listened to by any chemotherapist, because he has standing with chemotherapists, although there are not more than a thousand chemotherapists, if that many, in the United States. The surgeons are the people that see the cancer patients first, and the surgeons are really loth to do anything with difficult drugs, because the patients complain, and it takes care, it takes time to take care of patients that have drugs that are difficult for them. You know? And certainly most are not enthusiastic, but they're gradually coming around notwithstanding, because they see too many good things happening.

Well, it will be interesting, say, in a year's time, to see what result this summary has achieved.

Yes. Well, we have to hope that it -- that we arrange good distribution for it, because it's terribly needed. There's a lot of information, but just not evaluted or not summarized.

You'd think that this would be something that the National Institute of Health would be interested in doing.

Yes, they would be, but they're afraid to distibuter recommend what